SG11202012228QA - MODIFIED Cas9 PROTEIN AND USE THEREOF - Google Patents
MODIFIED Cas9 PROTEIN AND USE THEREOFInfo
- Publication number
- SG11202012228QA SG11202012228QA SG11202012228QA SG11202012228QA SG11202012228QA SG 11202012228Q A SG11202012228Q A SG 11202012228QA SG 11202012228Q A SG11202012228Q A SG 11202012228QA SG 11202012228Q A SG11202012228Q A SG 11202012228QA SG 11202012228Q A SG11202012228Q A SG 11202012228QA
- Authority
- SG
- Singapore
- Prior art keywords
- cas9 protein
- modified cas9
- modified
- protein
- cas9
- Prior art date
Links
- 108091033409 CRISPR Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682244P | 2018-06-08 | 2018-06-08 | |
PCT/JP2019/022795 WO2019235627A1 (ja) | 2018-06-08 | 2019-06-07 | 改変されたCas9タンパク質及びその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012228QA true SG11202012228QA (en) | 2021-01-28 |
Family
ID=68770337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012228QA SG11202012228QA (en) | 2018-06-08 | 2019-06-07 | MODIFIED Cas9 PROTEIN AND USE THEREOF |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220017881A1 (de) |
EP (1) | EP3805386A4 (de) |
JP (1) | JP7412001B2 (de) |
KR (1) | KR20210025046A (de) |
CN (1) | CN112513266A (de) |
AU (1) | AU2019281158A1 (de) |
BR (1) | BR112020024992A2 (de) |
CA (1) | CA3103088A1 (de) |
IL (1) | IL279178A (de) |
MX (1) | MX2020013158A (de) |
SG (1) | SG11202012228QA (de) |
WO (1) | WO2019235627A1 (de) |
ZA (1) | ZA202100092B (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3976785A1 (de) | 2019-05-28 | 2022-04-06 | Astellas Pharma Inc. | Verfahren zur behandlung von muskeldystrophie durch anvisierung des dmpk-gens |
WO2021230385A1 (en) | 2020-05-15 | 2021-11-18 | Astellas Pharma Inc. | Method for treating muscular dystrophy by targeting utrophin gene |
JP2023539631A (ja) * | 2020-08-31 | 2023-09-15 | 株式会社モダリス | Dux4遺伝子を標的とした顔面肩甲上腕型筋ジストロフィーの治療方法 |
AR124143A1 (es) | 2020-11-25 | 2023-02-15 | Astellas Pharma Inc | Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008008523A1 (en) * | 2006-07-14 | 2008-01-17 | Regents Of The University Of Minnesota | COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE |
JP2010505437A (ja) * | 2006-10-13 | 2010-02-25 | ノボ ノルディスク ヘルス ケア アーゲー | 塩基性タンパク質タグに融合したプロセシング酵素 |
WO2015048149A1 (en) * | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
KR20170042794A (ko) * | 2014-09-01 | 2017-04-19 | 브이아이비 브이지더블유 | 돌연변이체 csgg 포어 |
CN107405399B (zh) * | 2015-01-02 | 2022-02-08 | 武田药品工业株式会社 | 针对血浆激肽释放酶和因子xii的双特异性抗体 |
CA2978314A1 (en) | 2015-03-03 | 2016-09-09 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
EP3303634B1 (de) * | 2015-06-03 | 2023-08-30 | The Regents of The University of California | Cas9-varianten und verfahren zur verwendung davon |
CN108290933A (zh) * | 2015-06-18 | 2018-07-17 | 布罗德研究所有限公司 | 降低脱靶效应的crispr酶突变 |
WO2016205759A1 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
JPWO2017010543A1 (ja) | 2015-07-14 | 2018-06-14 | 国立大学法人 東京大学 | 改変されたFnCas9タンパク質及びその使用 |
US20190177710A1 (en) * | 2016-06-15 | 2019-06-13 | Toolgen Incorporated | Method For Screening Target Specific Nuclease Using Multi-Target System Of On-Target And Off-Target And Use Thereof |
SG10201913505WA (en) | 2016-10-17 | 2020-02-27 | Univ Nanyang Tech | Truncated crispr-cas proteins for dna targeting |
EP3625338A4 (de) | 2017-05-19 | 2021-01-20 | Tsinghua University | Konstruktion eines durch erweiterte guide-rna optimierten minimalen sacas9-crispr/cas-systems zur geneditierung und transkriptionsregulierung |
WO2019089910A1 (en) * | 2017-11-01 | 2019-05-09 | Ohio State Innovation Foundation | Highly compact cas9-based transcriptional regulators for in vivo gene regulation |
MX2021005720A (es) * | 2018-11-16 | 2021-07-21 | Astellas Pharma Inc | Metodo para tratar la distrofia muscular mediante el direccionamiento del gen de utrofina. |
-
2019
- 2019-06-07 KR KR1020217000588A patent/KR20210025046A/ko unknown
- 2019-06-07 MX MX2020013158A patent/MX2020013158A/es unknown
- 2019-06-07 EP EP19815297.7A patent/EP3805386A4/de active Pending
- 2019-06-07 CN CN201980037466.XA patent/CN112513266A/zh active Pending
- 2019-06-07 BR BR112020024992-0A patent/BR112020024992A2/pt unknown
- 2019-06-07 CA CA3103088A patent/CA3103088A1/en active Pending
- 2019-06-07 US US16/972,920 patent/US20220017881A1/en active Pending
- 2019-06-07 AU AU2019281158A patent/AU2019281158A1/en not_active Abandoned
- 2019-06-07 JP JP2020523211A patent/JP7412001B2/ja active Active
- 2019-06-07 WO PCT/JP2019/022795 patent/WO2019235627A1/ja unknown
- 2019-06-07 SG SG11202012228QA patent/SG11202012228QA/en unknown
-
2020
- 2020-12-03 IL IL279178A patent/IL279178A/en unknown
-
2021
- 2021-01-06 ZA ZA2021/00092A patent/ZA202100092B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3805386A1 (de) | 2021-04-14 |
MX2020013158A (es) | 2021-04-29 |
CN112513266A (zh) | 2021-03-16 |
ZA202100092B (en) | 2021-10-27 |
JPWO2019235627A1 (ja) | 2021-06-24 |
IL279178A (en) | 2021-01-31 |
KR20210025046A (ko) | 2021-03-08 |
JP7412001B2 (ja) | 2024-01-12 |
AU2019281158A1 (en) | 2021-01-14 |
EP3805386A4 (de) | 2022-03-23 |
CA3103088A1 (en) | 2019-12-12 |
BR112020024992A2 (pt) | 2021-03-23 |
WO2019235627A1 (ja) | 2019-12-12 |
US20220017881A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3633034A4 (de) | Modifiziertes cas9-protein und verwendung davon | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
ZA202103259B (en) | Modified cas9 protein, and use thereof | |
EP3680331A4 (de) | Modifiziertes cas9-protein und verwendung davon | |
ZA202100092B (en) | Modified cas9 protein and use thereof | |
ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
SG11202011000SA (en) | Taste and flavor-modifier proteins | |
IL277007A (en) | Therapeutic ANTI-SPLA2-GIB antibodies and their uses | |
IL287690A (en) | Antibodies against hvem and their use | |
IL280808A (en) | OX40-binding polypeptides and their uses | |
ZA201907063B (en) | Insecticidal proteins and methods for their use | |
SG11202104912SA (en) | Fusion protein and use thereof | |
SG11202110400QA (en) | Fusion protein and use thereof | |
SG11202006669RA (en) | Peptides and uses thereof | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
EP3882263A4 (de) | Glucagon-abgeleitetes peptid und seine verwendung | |
EP3816186A4 (de) | Pd-l1-bindende polypeptide und verwendung davon | |
GB202201001D0 (en) | Polypeptide and use thereof | |
SG11202111462VA (en) | Asx-specific protein ligases and uses thereof | |
GB201802122D0 (en) | Product and use | |
IL289531A (en) | cd38 binding agents and uses thereof | |
IL288828A (en) | Binding factors - cd38 and their use | |
IL280369A (en) | Myokines and their uses | |
EP3947418C0 (de) | Peptide und verwendung davon | |
GB201906914D0 (en) | Substituted naphtahlene diimdes and their use |